EP4629970A1 — Formulation comprising edoxaban and preparation thereof
Assigned to Synthon BV · Expires 2025-10-15 · 1y expired
What this patent protects
The invention relates to the tablet composition comprising edoxaban obtained by the direct compression process comprising the step of co-blending edoxaban and first portion of mannitol, wherein the weight ratio of edoxaban and first portion of mannitol is from 1:1 to 1:2.5.
USPTO Abstract
The invention relates to the tablet composition comprising edoxaban obtained by the direct compression process comprising the step of co-blending edoxaban and first portion of mannitol, wherein the weight ratio of edoxaban and first portion of mannitol is from 1:1 to 1:2.5.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.